cagrilintide
Peptideexperimental
Clinical trial activity
42 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
18
Phase 2
24
Phase 3
18
Phase 4
0
Earliest trial started Dec 1, 2014 (NCT02300844)
Timeline
Indications
Mechanism of action
Amylin receptor AMY1, CALCR/RAMP1 agonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4802169 ↗
Also known as
- nnc0174-0833
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07282613 | Phase 3 | Aug 4, 2026 | Novo Nordisk |
| NCT07253285 | Phase 3 | Jan 8, 2026 | Novo Nordisk |
| NCT07220642 | Phase 3 | Nov 5, 2025 | Novo Nordisk |
| NCT07220759 | Phase 3 | Nov 5, 2025 | Novo Nordisk |
| NCT07184086 | Phase 1 | Sep 26, 2025 | Novo Nordisk |
| NCT07010432 | Phase 1 | Jun 12, 2025 | Novo Nordisk |
| NCT07011667 | Phase 3 | Jun 3, 2025 | Novo Nordisk |
| NCT06780449 | Phase 3 | Feb 10, 2025 | Novo Nordisk |
| NCT06797869 | Phase 2 | Jan 29, 2025 | Novo Nordisk |
| NCT06719011 | Phase 1 | Dec 3, 2024 | Novo Nordisk |
| NCT06716307 | Phase 1 | Dec 2, 2024 | Novo Nordisk |
| NCT06534411 | Phase 3 | Nov 5, 2024 | Novo Nordisk |
| NCT06388187 | Phase 3 | Jun 24, 2024 | Novo Nordisk |
| NCT06409130 | Phase 2 | May 20, 2024 | Novo Nordisk |
| NCT06403761 | Phase 1 | May 6, 2024 | Novo Nordisk |
| NCT06131372 | Phase 2 | Apr 1, 2024 | Novo Nordisk |
| NCT06323161 | Phase 3 | Mar 26, 2024 | Novo Nordisk |
| NCT06323174 | Phase 3 | Mar 19, 2024 | Novo Nordisk |
| NCT06289504 | Phase 1 | Feb 27, 2024 | Novo Nordisk |
| NCT06207877 | Phase 1 | Feb 23, 2024 | Novo Nordisk |
Showing 20 of 42 trials
Page 1 / 3
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novo Nordisk | For profit | 42 | 42 | 3 | 2014 |
1 organizations
Page 1 / 1